Abstract
Almost all human cancers have accumulated multiple genetic lesions including oncogenes. It is often unknown whether an oncogene is continuously required for tumorigenesis. Furthermore, it is very difficult to target an essential oncogene with drugs without affecting the corresponding nonmutated protooncogene or related factors. The recent discovery of RNA interference and the application of small interfering RNAs in mammalian cell culture provide now tools to examine the role of oncogenes in tumor development. Furthermore, oncogene-specific siRNAs may become promising candidates for more cancer-specific therapeutic approaches. This review discusses the potential and the limitations of oncogene-targeting siRNAs and describes examples for the application of siRNAs in the functional analysis of oncogenes.
Keywords: rna interference, sirna, shrna, tumorigenesis, cancer, leukemia
Current Pharmaceutical Biotechnology
Title: Oncogene Suppression by Small Interfering RNAs
Volume: 5 Issue: 4
Author(s): Olaf Heidenreich
Affiliation:
Keywords: rna interference, sirna, shrna, tumorigenesis, cancer, leukemia
Abstract: Almost all human cancers have accumulated multiple genetic lesions including oncogenes. It is often unknown whether an oncogene is continuously required for tumorigenesis. Furthermore, it is very difficult to target an essential oncogene with drugs without affecting the corresponding nonmutated protooncogene or related factors. The recent discovery of RNA interference and the application of small interfering RNAs in mammalian cell culture provide now tools to examine the role of oncogenes in tumor development. Furthermore, oncogene-specific siRNAs may become promising candidates for more cancer-specific therapeutic approaches. This review discusses the potential and the limitations of oncogene-targeting siRNAs and describes examples for the application of siRNAs in the functional analysis of oncogenes.
Export Options
About this article
Cite this article as:
Heidenreich Olaf, Oncogene Suppression by Small Interfering RNAs, Current Pharmaceutical Biotechnology 2004; 5 (4) . https://dx.doi.org/10.2174/1389201043376733
DOI https://dx.doi.org/10.2174/1389201043376733 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Curcumin on Microsomal Enzyme Activities: Drug Interaction and Chemopreventive Studies
Current Medicinal Chemistry Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience
Current Radiopharmaceuticals Processed Foods, Dysbiosis, Systemic Inflammation, and Poor Health
Current Nutrition & Food Science SNAP-Tag Technology: A Powerful Tool for Site Specific Conjugation of Therapeutic and Imaging Agents
Current Pharmaceutical Design Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Anticancer Potential of Doxorubicin in Combination with Green-Synthesized Silver Nanoparticle and its Cytotoxicity Effects on Cardio-Myoblast Normal Cells
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Potential of Essential Oil-based Microemulsions: Reviewing State-of-the-art
Current Drug Delivery iNOS: A Potential Therapeutic Target for Malignant Glioma
Current Molecular Medicine Fe3O4 Nanoparticles Mediated Synthesis of Novel Isatin-dihydropyrimidinone Hybrid Molecules as Antioxidant and Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Anticancer Activity of Selenium Nanoparticles <i>In Vitro</i> Studies
Anti-Cancer Agents in Medicinal Chemistry Endoglin (CD105): A Target for Anti-angiogenetic Cancer Therapy
Current Drug Targets Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Recapitulation of Cancer Nanotherapeutics
Current Nanomedicine Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery ThermoTRP Channels in Nociceptors: Taking a Lead from Capsaicin Receptor TRPV1
Current Neuropharmacology Topoisomerase I-DNA Complex Stability Induced by Camptothecins and Its Role in Drug Activity&#
Current Medicinal Chemistry - Anti-Cancer Agents Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Current Pharmaceutical Design Synthesis and Cytotoxic Evaluation of Novel Symmetrical Taspine Derivatives as Anticancer Agents
Medicinal Chemistry